Skip to main content
SleepCited

Kava per Problemi di sonno legati all'ansia

A

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dkava\u0026condition\u003Danxiety\u002Drelated\u002Dsleep'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

In sintesi

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

Key Study Findings

Case Reports n=1 6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None vs: None Outcome: acute kava dermopathy with sebaceous gland necrosis Effetto: None None

Popolazione: 41-year-old Australian woman consuming kava for anxiety and insomnia

Case Reports n=1 Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None vs: None Outcome: Resolution of kava withdrawal symptoms Effetto: None None

Popolazione: 45-year-old man with kava and kratom withdrawal

Other Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract vs: Placebo Outcome: Tobacco cessation via stress/insomnia management Effetto: None None

Popolazione: Adult smokers (trial protocol)

Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None vs: Vehicle control Outcome: Acute oral toxicity, antinociceptive activity Effetto: None None

Popolazione: Animal model

Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None vs: None Outcome: Sleep quality improvement Effetto: None None

Popolazione: Insomnia patients

Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: Kava users

Key Statistics

23

Studi

2043

Partecipanti

Mixed

A

Grado

Referenced Papers

The American journal … 2025 1 citazioni
Journal of psychosocial … 2022 2 citazioni
Combinatorial chemistry & … 2021 16 citazioni
Chemical research in … 2019 6 citazioni
Journal of medicinal … 2018 19 citazioni
Sleep medicine reviews 2015 152 citazioni
Advances in pharmacological … 2011 79 citazioni
Integrative cancer therapies 2004 59 citazioni
Human psychopharmacology 2003 45 citazioni
Phytotherapy research : … 2001 74 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

sleep:
120-250 mg kavalactones/day, 1-2 hrs before bed

Limite massimo: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None 6 weeks Negative 1
None -- Positive 1
AB-free kava extract -- Mixed --
None -- Positive --
None -- Mixed --
None -- Mixed --
None -- Mixed --
not specified -- Positive --

Momento migliore per l'assunzione: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision

Safety & Side Effects

Effetti collaterali segnalati

  • Drowsiness and reduced coordination
  • Hepatotoxicity (rare but serious — consult healthcare provider)
  • Skin rash (kava dermopathy) with chronic high-dose use
  • GI discomfort

Interazioni note

  • Alcohol — increased hepatotoxicity risk and CNS depression
  • Hepatotoxic medications (acetaminophen, statins) — additive liver stress
  • Benzodiazepines and sedatives — additive CNS depression
  • CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
  • Levodopa and dopaminergic drugs — kava may reduce efficacy

Livello di assunzione massimo tollerabile: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Kava help with Problemi di sonno legati all'ansia?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Problemi di sonno legati all'ansia management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Problemi di sonno legati all'ansia?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Problemi di sonno legati all'ansia?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.